CECLOR
LOE ApproachingNDAORALFOR SUSPENSION
Approved
Apr 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CECLOR is an oral suspension small-molecule antibiotic approved in 1979 by Eli Lilly. The specific mechanism of action and therapeutic indications are not detailed in available data, but the formulation suggests treatment of bacterial infections in pediatric or patient populations requiring liquid dosing. As a legacy NDA product, it represents a mature, well-established therapeutic option in its class.
LOE Approaching
Declining commercial relevance with LOE approaching suggests smaller team size and shift from growth to maintenance focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CECLOR currently shows zero linked job openings, reflecting its mature market status and limited growth trajectory. Career opportunities center on commercial maintenance, regulatory compliance, and operational efficiency rather than innovation.
Brand ManagerField Sales Representative
Worked on CECLOR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.